South Korea Accelerates Nipah Virus Vaccine Development Amid Pandemic Concerns

South Korea is actively pursuing the development of a domestically produced vaccine for Nipah virus, a highly dangerous zoonotic disease with a fatality rate ranging from 40% to 75%. This initiative, spearheaded by the Korea Disease Control and Prevention Agency (KDCA) and the National Institute of Health (NIH), aims to proactively address the potential for a future pandemic caused by this virus. Currently, no commercially available vaccines or treatments exist for Nipah virus, prompting the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) to classify it as a priority disease for research and development.

Rising Global Concern Over Nipah Virus

Nipah virus is transmitted from person to person and is naturally hosted by bats. Its high fatality rate and lack of existing countermeasures have raised significant global health concerns. The KDCA recognizes the potential for local outbreaks to escalate into a wider pandemic, driving the urgency of this vaccine development program. KDCA and NIH are collaborating with domestic companies to accelerate the process.

A Multi-Pronged Approach to Vaccine Development

The KDCA is employing a comprehensive strategy, leveraging domestic technological capabilities and collaborating with companies like EuBiologics. The development program utilizes both recombinant protein and messenger RNA (mRNA) platforms, ensuring a diversified approach to vaccine candidate creation. This includes securing vaccine candidates, applying immune booster platforms, and utilizing artificial intelligence technologies. EuBiologics is focusing on a nanoparticle-based adjuvanted vaccine candidate.

Timeline and Key Milestones

The KDCA has outlined a clear timeline for the Nipah virus vaccine development:

• 2026: Animal model efficacy evaluations and establishment of Good Manufacturing Practice (GMP) production processes for vaccine candidates are actively underway.
• 2027-2028: Safety evaluations of the vaccine candidates will be conducted.
• 2029-2030: Phase 1 clinical trials are planned to start.

Broader Pandemic Preparedness Efforts

This Nipah virus vaccine initiative is part of a larger “Mid- to Long-Term Plan for New Infectious Disease Pandemic Preparedness” established in 2023. The KDCA is prioritizing vaccine development for nine infectious diseases, including COVID-19, influenza, SFTS, chikungunya, RSV, epidemic hemorrhagic fever with renal syndrome (Hantaan), Lassa, and dengue, alongside Nipah virus. This demonstrates a commitment to strengthening domestic vaccine development capabilities and proactively addressing potential future health crises.

Collaboration and Future Outlook

Director of the Korea Disease Control and Prevention Agency, Lim Seung-kwan, emphasized the importance of continued collaboration with domestic companies and other partners to enhance the nation’s preemptive response system for new infectious diseases. The goal is to secure a domestically produced Nipah virus vaccine and contribute to global efforts in combating this high-risk pathogen.